Methylated DNA/RNA in Body Fluids as Biomarkers for Lung Cancer

Yan Lu1, Shulin/SL Li2, Shiguo/SG Zhu3, Yabin/YB Gong1, Jun/J Shi1 and Ling/ L Xu1*

Abstract
DNA/RNA methylation plays an important role in lung cancer initiation and progression. Liquid biopsy makes use of cells, nucleotides and proteins released from tumor cells into body fluids to help with cancer diagnosis and prognosis. Methylation of circulating tumor DNA (ctDNA) has gained increasing attention as biomarkers for lung cancer. Here we briefly introduce the biological basis and detection method of ctDNA methylation, and review various applications of methylated DNA in body fluids in lung cancer screening, diagnosis, prognosis, monitoring and treatment prediction. We also discuss the emerging role of RNA methylation as biomarkers for cancer.

Keywords: Lung cancer, Liquid biopsy, ctDNA, Circulating RNA, Methylation

Background
Lung Cancer is the second most common malignant tumor and the leading cause of cancer deaths worldwide [1]. Smoking tobacco is the primary risk factor for lung cancer [1, 2]. Early detection and surgery offer the best chance for survival. Screening using low-dose computed tomography (LDCT) has been proved to improve early detection and reduce mortality [3]. However, LDCT is far from satisfactory as a screen tool due to its low specificity [4]. And 30% of patients with as early as stage I lung cancer experience relapse after surgery and recommended adjuvant chemotherapy [5], and for advanced and metastatic disease that is inoperable, patients have to receive radiotherapy, chemotherapy, targeted therapy and immunotherapy and experience remission, recurrence and metastasis. Surveillance plan and treatment decisions are conventionally made based on group statistics and not precise or personalized. The overall 5 year survival of lung cancer is only 17.7% [6]. Therefore, effective biomarkers for early detection, diagnosis, prognosis and monitoring of lung cancer are in urgent need.

Lung cancer is characterized by diverse genetic alterations, making the development of reliable and feasible DNA-based biomarkers very challenging. Epigenetic changes, referred to changes in gene regulation that are not attributed to changes in DNA sequence [7], are relatively consistent in carcinogenesis. Epigenetic abnormalities, comprising alterations in DNA/RNA methylation, histone modifications, nucleosome positioning and non-coding RNAs, are considered hallmarks of cancer initiation and progression [8]. Recent advances in the field of lung cancer epigenetics have revealed promising biomarkers, particularly involving ctDNA methylation and an emerging role of RNA methylation.

DNA Hypermethylation and Hypomethylation in Lung Cancer

Hypermethylation
DNA methylation occurs at carbon-5 position of cytosine within CpG dinucleotides that scattered in human genome. The vast majority of the genome contains few CpGs, and most of them are methylated in normal cells. In contrast, around 2% of the genome contains high density of CpG in regions named CpG islands (CGIs) [9] that locate in 50–60% of gene promoters and are often unmethylated during normal development and in adult cells [10]. Methylated CGIs is generally a repressive mark of transcription initiation [11] that hinders the binding of activating transcriptional factors to DNA sequences [12, 13] and recruits inhibitory proteins [14, 15]. The cancer genome is globally hypomethylated, except for the dense methylation at CGIs that is associated with the permanent repression of tumor suppressor genes and other cancer-related genes, thus promotes...
cancer progression [11, 16]. In non-small cell lung cancer (NSCLC), CGI hypermethylation is associated with diagnosis [17, 18], staging [19], cigarette smoking [20], histological subtype [19, 21, 22], molecular subtypes [23–25], progression [26], prognosis [27–30], and used as a potential therapeutic target [31].

Hypomethylation
DNA hypomethylation (m5C residues replaced by unmethylated C residues) is the initial epigenetic abnormality recognized in human tumors but has been ignored for a long time [32]. DNA methylation in repetitive sequences could be essential to maintain chromosomal integrity. Studies confirm that DNA hypomethylation is the most constant companion to hypermethylation of the genome in cancer [33–35], lung cancer included [36]. DNA hypomethylation in repetitive sequence occurred in early stage of squamous cell lung cancer [33], and individuals with hypomethylation in repetitive element are at a high risk of developing and dying from cancer [34]. Therefore, hypomethylation could be used as a screening, diagnosis and prognosis biomarker.

Circulating Tumor DNA (ctDNA) Methylation
Biological Basis of ctDNA
Circulating cell-free DNA (cfDNA) is a mixture of single or double-stranded DNA in circulation released from different tissues including tumor. Since it is difficult to separate ctDNA from cfDNA originated from non-cancer tissues, careful selection of control group and target genes in a clinical trial is critical. As a result of nuclease digestion during the release processes, cfDNA are usually short fragments with generally very low concentration [37, 38]. In cancer patients, level of cfDNA is elevated with ctDNA as a substantial fraction ranging from <0.05 [39] to 90% [40], depending on tumor volume, localization, vascularization, hepatic and renal clearance [41]. ctDNA mostly results from apoptosis and necrosis of primary and metastatic tumor [40]. Recent studies have also reported other sources of ctDNA, such as circulating tumor cells (CTCs) [42, 43], and exosomes released by tumor cells [44]. The concordant epigenetic alterations between ctDNA and corresponding tumor tissue DNA [45–48] make ctDNA methylation a promising biomarker for cancer diagnosis and prognosis. Other sources of methylated DNA from liquid biopsy have also been reported, such as cell-surface-bound circulating DNA (csbDNA) [49, 50], Buffy coat DNA [51], peripheral lymphocyte DNA [52, 53], peripheral leukocyte DNA [54, 55], sputum [56] and exhaled breath condensate (EBC) [57].

cDNA Extraction Method
cfDNA can be isolated from both plasma and serum. Although cfDNA from serum has been reported with higher quantity [58], its separation process is more demanding to prevent DNA released from the lysis of blood cells [37]. Anyway, it is essential to prepare DNA using very fresh serum/plasma. Therefore, it is highly recommended to process blood sample and separate DNA as soon as possible (within 4 h for serum and 8 h for plasma) [38]. The volume of blood sample necessary to obtain sufficient cfDNA depends on the downstream analysis method. Classical DNA purification methods used for tissues are not suitable for ctDNA [59], and lots of extraction kits designed for cfDNA have become available [59–61].

cDNA Methylation Detection Method
Detection of ctDNA methylation has evolved from a few candidate genes to thousands of CpG sites, and recently to whole genome methylation analysis. Detection method of ctDNA methylation can be divided into three groups according to basic principles: sodium bisulfite conversion-dependent methods, restriction enzyme-dependent methods and affinity enrichment-dependent methods.

Bisulfite Conversion-Dependent Methods
Sodium bisulfite conversion is the most widely used method to distinguish unmethylated cytosines from methylated ones, and can be coupled with various downstream detection technologies, for example, microarrays, next-generation sequencing (NGS), PCR-based assays, pyrosequencing, quantitative methylation-specific polymerase chain reaction (qMSP) and whole-genome shotgun bisulfite sequencing (WGSBS). Sodium bisulfite rapidly deaminates unmethylated cytosines to uracils, whereas methylated cytosines are only slowly converted [62]. However, bisulfite treatment can induce random DNA breaks, resulting in short single-stranded DNA fragments, especially for cfDNA that is sparse and highly fragmented. Several bisulfite conversion kits with improved recovery of cfDNA have become commercially available, mainly through reducing the incubation time of DNA with bisulfite conversion reagent [63, 64]. Bisulfite treatment also induces reduction in sequence complexity, and cannot distinguish 5-methylcytosines from 5-hydroxymethylcytosines [65], both resulting in compromising efficiency.

Restriction Enzyme-Dependent Methods
Restriction enzyme-dependent method utilizes methylation-sensitive restriction enzymes (MSREs) that solely cut unmethylated DNA, so that the rate of false-positives due to incomplete DNA digestion can be prevented. MSREs can be coupled with some downstream detection technologies, for example, differential methylation hybridization (DMH), MCA with microarray hybridization...
(MCAM), HpaII tiny fragment enrichment by ligation-mediated PCR (HELP), combined bisulfite restriction analysis (COBRA) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). The disadvantage of this method is only a particular pattern of CpG sites can be analyzed.

**Affinity Enrichment-Dependent Methods**
Affinity enrichment-dependent methods utilize specific antibodies interacted with methylated cytosine or methyl-binding proteins to enrich methylated DNA, before further examination with whole-genome analysis by array-based hybridization or next generation sequencing as well as gene-specific determination by PCR. Examples include MethylCpG Binding Domain MBD2 proteins (MBD, also termed Methyl Cap), methylated DNA immunoprecipitation (MeDIP) and methylated CpG island recovery assay (MIRA) [66]. Low recovery rate of methylated DNA is the main disadvantage [67–69].

**Smoking and Lung-Cancer-Related DNA Methylation from Liquid Biopsy**
Various factors associated with lung cancer have been shown to alter epigenome that is lung-cancer related, for example aging, chronic inflammation and cigarette smoking [70, 71]. Russo AL et al. report hypermethylation at ECAD, p16, MGMT and DAPK from peripheral lymphocytes DNA as smoking specific epigenome alternating [53]. Baglietto L et al. identified 6 CpGs hypomethylation in 5 genes (AHRR, F2RL3, 2q37.1, 6p21.33 and 12q14.1) from peripheral blood related to smoking that may raise lung cancer risk, and 5 of them were lowest for current smokers and increased with time since quitting for former smokers. Methylation at these 6 CpGs can help improving prediction of lung cancer risk [72].

Gao X et al. demonstrated the impact of tobacco smoking on DNA methylation at 8 lung-cancer-related genes (KLF6, STK32A, TERT, MSH5, ACTA2, GATA3, VTI1A and CHRNA5). DNA hypomethylation in 11 loci was linked to current smokers, compared with never smokers and 10 of them showed significant associations with life-time cumulative smoking [73]. Interestingly, a study from Davis A et al. does not support the association between global blood DNA methylation and the risk of lung cancer in non-smoking women [74], and supports the association between smoking, DNA methylation and lung cancer from opposite side. These studies demonstrate the role of smoking in promoting lung cancer through DNA methylation.

**Methylated DNA from Liquid Biopsy as Biomarkers for Lung Cancer**
Tumor-specific methylation of ctDNA are promising biomarkers to help screening, diagnosis, prognosis, monitoring and prediction of therapy response. Due to relatively low efficiency of single biomarker, it is more common to use combination of ctDNA methylations to improve sensitivity and specificity. Some researchers explored the potential role of DNA methylation as a target for lung cancer treatment. Methylated DNA can also be acquired from csbDNA [49, 50], buffy coat DNA [51], and blood cell [75] including lymphocyte [52, 53] and leukocyte [54, 55]. DNA methylations from EBC [57] and sputum [56] are also reported to be associated with lung cancer diagnosis and prognosis.

**Screening and Diagnosis**
Methylation occurs at early stage of carcinogenesis, and has become an attractive biomarker for cancer screening and early detection, especially for ctDNA methylation with its convenience and non-invasion. Many studies have reported the potential of ctDNA methylations for the screening and diagnosis of lung cancer. Various gene promoter methylations (Table 1) and their combinations (Table 2) were found to be effective in discriminating lung cancer patients from non-cancer controls. Biomarkers mostly investigated include SHOX2 [46, 47, 76, 77], RASSF1A [54, 75, 78–80], RARB2 [50, 78], LINE-1 [49, 51], P16 [54, 57, 81–83], MGMT [53, 79, 81], DAPK [53, 56, 81], APC [47, 79, 84] and DLEC1 [47, 85]. For example, Powrózek T et al. evaluated DCLK1 methylation status in DNA isolated from peripheral blood plasma from 65 lung cancer patients and 95 healthy individuals. DCLK1 promoter methylation was detected in 32 lung cancer patients (49.2%) and 8 healthy individuals (8.4%). The methylation of the region before transcription start site (TSS) and the region after TSS of DCLK1 gene was detected in 28 and 11 patients, respectively. In seven cases (10.8%), the DCLK1 promoter methylation in both regions was reported. The methylation was observed slightly frequent in patients with small cell lung cancer [17]. Weiss G et al. examined 330 plasma specimens in three independent case–control studies, resulting in a panel of SHOX2 and PTGER4 to distinguish lung cancer from control (area under the receiver operating characteristic curve = 91–98%). A validation study with 172 patient samples demonstrated good performance in distinguishing LC patients from subjects without malignancy (area under the curve = 0.88) [77].

A large proportion of results mentioned above are based on studies comparing advanced lung cancer with healthy control. To avoid bias and improve the screening and early diagnosis efficiency, studies should include specifically early stage LC and non-cancer control.

**Monitoring and Prognosis**
DNA methylation can be used to indicate risk of cancer recurrence due to residual disease after surgery/
chemotherapy. Due to its short half-life, ctDNA can reflect tumor burden sensitively and allows 'real-time' monitoring of tumor dynamics. Persistence of ctDNA in blood after surgery is associated with poor prognosis [39]. In early stage like stage Ib NSCLC, benefit from adjuvant chemotherapy is controversial, and ctDNA methylation might be used as a prognostic biomarker to define patients at high risk of recurrence who may benefit from chemotherapy. In patients with high probability of recurrence after surgery, monitoring with ctDNA methylation can be a good surrogate to image and tumor markers, and improve clinical outcome with early detection of recurrence [45, 86].

Ponomaryova AA et al. investigated the methylation status in plasma of 32 healthy donors and 60 lung cancer patients before and after treatment, and found that chemotherapy and total tumor resection resulted in a significant decrease in the index of methylation for RARB2 and RASSF1A, and methylation of RARB2 detected within follow-up period manifested disease relapse at 9 months [78]. Schmidt B et al. demonstrated better survival in patients with low SHOX2 promotor methylation 1 week after the start of chemotherapy [87].

| DNA methylation | Body fluid | Method | Number of cases | Number of controls | Sensitivity (%)/specificity (%) or main findings | References |
|-----------------|------------|--------|-----------------|-------------------|-------------------------------------------------|------------|
| SHOX2           | plasma     | qMSP   | 222             | 189               | 60/90                                           | [76]       |
| RARB2           | plasma     | MSP    | 52              | 26                | 63/51                                           | [50]       |
| DCLK1           | plasma     | qMSP   | 38              | 31                | 80.65/78.57                                     | [46]       |
| SEPT9           | plasma     | qMSP   | 65              | 95                | 49.2/91.6                                       | [17]       |
| DLEC1           | plasma     | qMSP   | 75              | 100               | 44.3/92.3                                       | [106]      |
| IEAA            | blood      | HM450K | 43              | 1986              | one unit increase in IEAA was associated with 50% higher risk for LC | [107]      |
| P16             | serum      | MSP    | 22              | 0                 | 14%                                             | [81]       |
| CDH1            | serum      | qMSP   | 76              | 30                | 62/70                                           | [79]       |
| DCC             | serum      | qMSP   | 76              | 30                | 35.5/100                                        | [79]       |
| CDH13           | plasma     | MSP    | 63              | 36                | 33/83                                           | [108]      |
| RARB2           | csbDNA     | MSP    | 52              | 26                | 70/63                                           | [50]       |
| RAS/FS1A        | serum/plasma| MSP   | 22              | 0                 | 18%                                             | [81]       |
| GSTP1           | serum      | MSP    | 22              | 0                 | 40%                                             | [80]       |
| MGMT            | serum      | MSP    | 22              | 0                 | 5%                                              | [81]       |
| RASSF1A         | serum      | NA     | 50              | 0                 | 18%                                             | [81]       |
| TMS1            | serum      | NA     | 50              | 0                 | 34%                                             | [80]       |
| APC             | Serum/plasma| MSP   | 89              | 50                | positive with LC diagnosis.                     | [75]       |
| LINE-1          | csbDNA     | MIRA   | 56              | 44                | AUC0.69                                         | [49]       |
| p53             | peripheral lymphocyte DNA | HpaII quantitative PCR | 100              | -                 | Hypomethylation was associated with a 2-fold increased risk for LC | [52]       |

qMSP quantitative methylation-specific PCR, F-MSP fluorescent methylation-specific PCR, HM450K HumanMethylation450K BeadChip Assay, MSP methylation-specific PCR, MIRA methylated CpG island recovery assay, LC lung cancer, SHOX2 short stature homeobox 2, DCLK1 doublecortin like kinase 1, SEPT9 septin9, IEAA intrinsic epigenetic age acceleration, RARB2 retinoic acid receptor B2, DLECT Deleted in lung and esophageal cancer 1, CDH1 cadherin 1, DCC DCC netrin 1 receptor, CDH13 cadherin 13, DAPK death-associated protein kinase, GSTP1 glutathione S-transferase P1, MGMT O6 - methylguanine-DNA-methyltransferase, RASSF1A ras association domain family 1 isoform A, APC adenomatous polyposis coli, p16 cyclin-dependent kinase inhibitor 2A, csbDNA cell-surface-bound circulating DNA, EBC exhaled breath condensate, NA not available.
Table 2: Combination of DNA methylation from liquid biopsy as Biomarkers for lung cancer diagnosis

| DNA methylation combination | Body fluid | Method       | Number of cases | Number of controls | Sensitivity% or specificity% or main findings | References |
|-----------------------------|------------|--------------|-----------------|--------------------|-----------------------------------------------|------------|
| RASSF1A/RARB2               | Plasma/csbDNA | qMSP       | 60              | 32                 | 87/75 (AUC0.755)                              | [78]       |
| SHOX2/PTGER4               | Plasma      | RT-PCR      | 117             | 122                | 67/90 or 90/73                                | [77]       |
| RTEL1/PCDHGB6              | cfDNA       | qMSP-PCR    | 70              | 80                 | 62.9/90                                      | [17]       |
| HOXD10/PAX9/PTPRN2/STAG3   | Serum       | MSRE/qPCR   | 23              | 23                 | 87.8/90                                      | [19]       |
| APC/RASSF1A/CDH13/1/LK1/DLEC1 | Plasma      | MSP         | 110             | 50                 | 83/70                                         | [47]       |
| APC/AIM1/CDH1/DCC/MGMT/RASSF1A | Serum     | qMSP        | 76              | 30                 | 84/57                                         | [79]       |
| DAPK/PAX5b/PAX5a/Dal1/GATA5/SULF2/CXCL14 | Sputum | MSP       | 40              | 90                 | 75/68                                         | [56]       |
| MGMT/DAPK/PAX5b/Dal1/DPCD200/Jph3/Kif1a | Serum | qMSP       | 64              | 64                 |                                              |            |

qMSP: quantitative methylation-specific PCR, RT-PCR: real-time PCR, MSTR: Methyltransferase-Sensitive Restriction Enzymes, CSB: cell-surface-bound circulating DNA, LC: lung cancer, SCCL: small cell lung cancer, RASSF1A: ras association domain family 1 isoform A, RARB2: retinoic acid receptor B2, SHOX2: short stature homeobox 2, PTGER4: prostaglandin E receptor 4, RTEL1: regulator of telomere elongation helicase 1, PCDHGB6: protocadherin gamma subfamily B, 6, HOXD10: homeobox D10, PAX9: paired box 9, PTPRN2: protein tyrosine phosphatase receptor type N2, STAG3: stromal antigen 3, APC: adenomatous polyposis coli, DLECT: Deleted in lung and esophageal cancer 1, CDH13: cadherin 13, KLK1: kallikrein 1, AIM1: absent in melanoma 1, CDH1: cadherin 1, DCC: DCC netrin 1 receptor, MGMT: O6 - methylguanine-DNA-methyltransferase, DAPK: death-associated protein kinase, PAX5b: paired box 5b, PAX5a: paired box 5a, GATA5: GATA binding protein 5, SULF2: sulfatase 2, CXCL14: C-X-C motif chemokine ligand 14, PCDH20: protocadherin 20, Jph3/junctophilin 3, CSF3R: colony stimulating factor 3 receptor, ERCC1: ERCC excision repair 1, FHIT: fragile histidine triad, RTL: relative telomere length, p16: cyclin-dependent kinase inhibitor 2A

Table 3: Methylation of DNA from liquid biopsy as biomarkers for lung cancer prognosis and prediction

| DNA methylation combination | Body fluid | Method          | Number of cases | Number of controls | Main findings                                           | References |
|-----------------------------|------------|-----------------|-----------------|--------------------|---------------------------------------------------------|------------|
| SHOX2                       | Plasma      | qMSP            | 36              | -                  | negative impact on survival                             | [87]       |
| RARB2/RASSF1A               | Plasma      | qMSP            | 26              | -                  | Reduced after neoadjuvant chemotherapy and surgery;      | [78]       |
| RARB2                       | Plasma      | qMSP            | 26              | -                  | increased before recurrence                             | [78]       |
| RASSF1A/APC                 | Plasma      | qMSP            | 316             | -                  | Elevated after chemotherapy, correlated with good response to cisplatin | [89]       |
| DCLK1                       | Plasma      | qMSP            | 65              | 95                 | negative impact on survival                             | [17]       |
| BRMS1                       | Plasma      | qMSP            | 122             | 24                 | negative impact on survival                             | [86]       |
| SOX17                       | Plasma      | qMSP            | 122             | 24                 | negative impact on survival                             | [45]       |
| SFN                         | Serum       | qMSP            | 115             | -                  | positive impact on survival with platinum-based chemotherapy | [88]       |
| CHFR                        | Serum       | qMSP            | 366             | -                  | negative impact on survival with second-line EGFR-TKIs, compared to chemotherapy | [90]       |
| smoCpGs                      | Whole blood | HM450K          | 60              | 1505               | predict LC mortality (HR=7.82)                          | [110]      |
| APC/RASSF1A/CDH13/CDKN2A    | Plasma      | MSP             | 45              | -                  | negative impact on PFS and OS                          | [31]       |

qMSP: quantitative methylation-specific PCR, HM450K: HumanMethylation450K BeadChip Assay, LC: lung cancer, PFS: progression free survival, OS: overall survival, SHOX2: short stature homeobox 2, RARB2: retinoic acid receptor B2, RASSF1A: ras association domain family 1 isoform A, APC: adenomatous polyposis coli, DCLK1: doublecortin like kinase 1, BRMS1: breast cancer metastasis suppressor-1, SOX17: sex determining region Y-box 17, SFN: stratatin, CHFR: checkpoint with forhead and ring finger domains, smoCpGs: smoking-associated CpGs, coxCpGs: Lung cancer-related CpGs, CDH13: cadherin 13, CDKN2A: cyclin dependent kinase inhibitor 2A
advanced and metastatic lung cancer, some biomarkers are associated with disease progression and survival, including BRMS1 [86], SOX17 [45], DCLK1 [17], and SFN (14-3-3 Sigma) promoter methylation [88] (Table 3).

Prediction of Therapy Response
cDNA provides a potential detection of early response to treatment, compared with conventional imaging or protein-based biomarkers. Several studies have reported the use of tumor-speciﬁc methylation to track patient’s response to therapy (Table 3). For example, Wang H et al. reported an elevated level of APC and RASSF1A promoter methylation in cDNA within 24 h after cisplatin-based therapy, consistent with chemotherapy-induced cell death [89]. The value of methylated cDNA to predict response to therapy has also been investigated. For example, Salazar F et al. reported that patients with unmethylated CHFR promoter survived longer when receiving EGFR tyrosine kinase inhibitors as second-line treatment, compared to conventional chemotherapy [90].

Target for Therapy
With the signiﬁcance of DNA methylation in cancer progression, epigenetic treatment became a potential therapeutic candidate. Effect of epigenetic therapy in lung cancer has been reported. Juergens RA et al. investigated combined epigenetic therapy with azacitidine and entinostat, inhibitors of DNA methylation and histone deacetylation respectively, in patients with recurrent metastatic NSCLC, and with demethylation of a set of 4 epigenetically silenced genes known to be associated with lung cancer in serial blood samples, resulted in objective and durable responses [31]. Further investigations of methylated cDNA as a treatment target are expected.

Emerging Role of RNA Methylation
RNA methylation was first described as a form of post-transcriptional modiﬁcation more than 40 years ago [91, 92]. But the exact mechanism and signiﬁcance of methylated RNA is just beginning to be appreciated. Among more than a hundred types of nucleotide modiﬁcations identiﬁed in different RNA molecules [93, 94], m6A modiﬁcation has attracted most attention owing to its potential to regulate gene expression reversibly. RNA with m6A modiﬁcation does not activateTLR3 [95, 96], leading to non-recognition of viral components, and may stimulate a pathway involved in cancer development [96–98]. RNA methylation may alter miRNA expression and mediate cancer cell migration [99]. RNA methylation may be involved in cancer stem cells speciﬁcation and disease progression [100]. The application of circulating RNA methylation in various types of cancer has been reported. For example, Murooka T et al. proved that serum miR-34b/c methylation can be used for the diagnosis and prognosis of malignant pleural mesothelioma [101]. Drugs that induced RNA demethylation might contribute to patient responses [102, 103]. Lian CG et al. reported another type of modiﬁcation in RNA, 5-hydroxymethyl cytosine (5hmC), as a signature for melanoma prognosis [104]. Further research on circulating RNA methylation in lung cancer is anticipated.

Conclusions and Perspectives
Lung cancer liquid biopsy has received increasing attention in recent years with its advantage as a non-invasive detection. Among the huge amount of information obtained from liquid biopsy, epigenetic alterations, especially DNA/RNA methylation, has been widely researched. cDNA/RNA methylation has been associated with the screening, diagnosis, prognosis, monitoring and treatment prediction of lung cancer. The advances in techniques enable detection of methylation from sparse and fragmented DNA/RNA. For example, it is now feasible to detect DNA/RNA methylation from single CTC [105]. However, the methodology is still in lack of standardization, which hinders the development of methylation studies in every aspect. It is urgent to establish standardized protocols from sample storage, cDNA/RNA extraction to methylation analysis. Translating circulating epigenetic biomarkers from clinical study to clinical routine for lung cancer is expected.

Abbreviations
AIM1: Absent in melanoma 1; APC: Adenomatous polyposis coli; BRMS1: Breast cancer metastasis suppressor-1; caCpGs: Lung cancer-related CpGs; CDH1: Cadherin 1; CDH13: Cadherin 13; CDKN2A: Cyclin dependent kinase inhibitor 2A; cDNA: Circulating cell-free DNA; CGs: CpG islands; CHFR: Checkpoint with forkhead and ring finger domains; COBRA: Combined Bisulﬁte Restriction Analysis; cDNA: Cell-surface-bound circulating DNA; CSF3R: Colony stimulating factor 3 receptor; CTCs: Circulating tumor cells; cDNA: Circulating tumor DNA; CXCL14: C-X-C motif chemokine ligand 14; DAPK: Death-associated protein kinase; DCC: DCC netrin 1 receptor; DCLK1: Doublecortin like kinase 1; DLEC1: Deleted in lung and esophageal cancer 1; DMH: Differential methylation hybridization; EBC: Exhaled breath condensate; ERCC1: ERCC excision repair 1; FHT: Fragile histidine triad; F-MS: Fluorescent methylation-speciﬁc PCR; GATA binding protein 5; GSTP1: Glutathione S-transferase P1; HELP: HpaII tiny fragment enrichment by ligation-mediated PCR; HM450K: HumanMethylation450K BeadChip Assay; HOXD10: Homeobox D10; Homeobox D10; IEAA: Intrinsic epigenetic age acceleration; Jph3: Junctophilin 3; KLK1: Kallikrein 1; LC: Lung cancer; LDCT: Low-dose computed tomography; MBD: MethylCpG Binding Domain protein 2; MCA: MCA with microarray hybridization; MeDIP: Methylated DNA immunoprecipitation; MGMT: O6 - methylguanine-DNA-methyltransferase; MIRA: Methylated CpG island recovery assay; MS-MLPA: Methylation-speciﬁc multiplex ligation-dependent probe ampliﬁcation; MSP: Methylation-speciﬁc PCR; MSREs: Methylation-Sensitive Restriction Enzymes; NA: Not available; NGS: Next-generation sequencing; OS: Overall survival; p16: Cyclin-dependent kinase inhibitor 2A; PAX5a: Paired box 5a; PAX5b: Paired box 5b; PAX9: Paired box 9; PCDH20: Protocadherin 20; PCDHGd6: Protocadherin gamma subfamily B; PFS: Progression free survival; PTGER4: Prostaglandin E receptor 4; PTPRN2: Protein tyrosine phosphatase receptor type N2; qMSP: Quantitative methylation-speciﬁc polymerase chain reaction; qPCR: Quantitative PCR; RARβ: Retinoic acid receptor β2; RASSF1A: Ras association domain family 1 isoform A; RTEL1: Regulator of telomere elongation helicase 1; RTL: Relative telomere length; SCLC: Small cell lung cancer; SEPT9: Septin9; SFN: Stratﬁn; SHOX2: Short stature homeobox 2; snoCpGs: Smoking-associated CpGs; SOX17: (sex determining region Y)-box.
Acknowledgements
Yao Xiaoxin helped with providing full-text download.

Funding
funded by Science and Technology Commission of Shanghai Municipality, key projects of traditional chinese medicine (16401970700). The funding body has no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.

Availability of Data and Materials
All data in this review is from publications found on pubmed.

Authors’ Contributions
LY, LS and XL chose this subject and made outlines. LY searched database, collected datas and wrote the manuscript. ZS, GY and SJ helped with data collection and analysis, and provided valuable opinions on the writing of the manuscript. All authors read and approved the final manuscript.

Competing Interests
The authors declare that they have no competing interests.

Consent for Publication
Not applicable.

Ethics Approval and Consent to Participate
Not applicable.

Consent for Publication
Not applicable.

Funding
No.2 oncology department, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine; No.110, Ganhe Rd, Shanghai, China. 2Department of Immunology and Pathogenic Biology, School of Basic Medical Sciences, Shanghai University of Traditional Chinese Medicine, 1200 Cai Lun Rd, Shanghai, China.

Received: 4 February 2017 Accepted: 2 March 2017

Published online: 17 March 2017

References
1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
2. Secretan B, Straif K, Baan R, et al. A Review of Human Carcinogens-Part E: Tobacco, Arecanut, Alcohol, Coal Smoke, and Salted Fish. Lancet Oncol. 2009;10:1033–4.
3. Team NLSR, Aberle DR, Adams AM, et al. Reduced Lung-cancer Mortality with Low-dose Computed Tomographic Screening. N Engl J Med. 2011;365:395–409.
4. Patz Jr EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in Low-dose Computed Tomography Screening for Lung Cancer. JAMA Intern Med. 2014;174:679–94.
5. Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: Prognostic Factors and Pathologic TNM Stage in Surgically Managed Non-small Cell Lung Cancer. J Thorac Oncol. 2009;4:792–801.
6. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2013, Based on November 2015 SEER Data Submission, Posted to the SEER Web Site, April 2016. Bethesda: National Cancer Institute; 2016. https://seer.cancer.gov/csr/1975_2013/. Accessed 3 Feb 2017.
7. Berger SL, Kozunides T, Shiekhattar R, et al. An Operational Definition of Epigenetics. Genes Dev. 2009;23:781–3.
8. Sharma S, Kelly TK, Jones PA. Epigenetics in Cancer. Carcinogenesis. 2010;31:27–35.
9.Baylin SB. The Cancer Epigenome: Its Origins, Contributions to Tumorigenesis, and Translational Implications. Proc Am Thorac Soc. 2012;9:64–5.
10. Baylin SB, Jones PA. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol. 2016b;8:a019505.
11. Bird A. DNA Methylation Patterns and Epigenetic Memory. Genes Dev. 2002;16:5–21.
12. Prendergast GC, Ziff EB. Methylation-sensitive Sequence-Specific DNA Binding by the c-Myb Basic Region. Science. 1991;251:186–9.
13. Watt F, Molloy PL. Cytosine Methylation Prevents Binding to DNA of a Helicase Cell Transfection Factor Required for Optimal Expression of the Adenovirus Major Late Promoter. Genes Dev. 1988;2:1136–43.
14. Nan X, Ng HH, Johnson CA, et al. Transcriptional Repression by the Methyl-CpG-binding Protein McCP2 Involves a Histone Deacetylase Complex. Nature. 1998;393:386–9.
15. Jones PL, Veenestra GT, Wade PA, et al. Methylated DNA and McCP2 Recruit Histone Deacetylase to Repress Transcription. Nat Genet. 1998;19:187–91.
16. Baylin SB, Jones PA. A Decade of Exploring the Cancer Epigenome - Biological and Translational Implications. Nat Rev Cancer. 2011;11:726–34.
17. Powrzek T, Krawczyk P, Nicoll M, et al. Methylation of the DCL1 Promoter Region in Circulating Free DNA and its Prognostic Value in Lung Cancer Patients. Clin Trans Oncol. 2016;18:398–404.
18. Tsou JA, Galler JS, Siegmund KD, et al. Identification of a Panel of Sensitive and Specific DNA Methylation Markers for Lung Adenocarcinoma. Mol Cancer. 2007;670.
19. Kontic M, Stojic J, Jovanovic D, et al. Aberrant Promoter Methylation of CDH13 and MGMT Genes is Associated with Clinicopathologic Characteristics of Primary Non-small-cell Lung Carcinoma. Clin Lung Cancer. 2012;13(4):297–303.
20. Sato T, Arai E, Kohno T, et al. Epigenetic Clustering of Lung Adenocarcinomas Based on DNA Methylation Profiles in Adjacent Lung Tissue: Its Correlation with Smoking History and Chronic Obstructive Pulmonary Disease. Int J Cancer. 2014;135:319–34.
21. Hawkes SE, Stem JE, Feng Q, et al. DNA Hypermethylation of Tumors from Non-small Cell Lung Cancer (NSCLC) Patients is Associated with Gender and Histologic Type. Lung Cancer. 2010;69:172–9.
22. Carvalho RH, Hou J, Haberle V, et al. Genomewide DNA Methylation Analysis Identifies Novel Methylated Genes in Non-small-cell Lung Carcinomas. J Thorac Oncol. 2013;8:562–73.
23. Walter K, Holcomb T, Januario T, et al. DNA Methylation Profiling Defines Clinically Relevant Biological Subsets of Non-small Cell Lung Cancer. Clin Cancer Res. 2012;18:2360–73.
24. Shinjo K, Okamoto Y, An B, et al. Integrated Analysis of Genetic and Epigenetic Alterations Reveals CpG Island Methylator Phenotype Associated with Distinct Clinical Characters of Lung Adenocarcinoma. Carcinogenesis. 2012;33:1277–85.
25. Cancer Genome Atlas Research Network. Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature. 2014;515:543–50.
26. Selamat SA, Galler JS, Joshi AD, et al. DNA Methylation Changes in Atypical Adenomatous Hyperplasia, Adenocarcinoma in Situ, and Lung Adenocarcinoma. PLoS One. 2011;6:e21443.
27. Brock MV, Hooker CM, Ota-Machida E, et al. DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer. N Engl J Med. 2008;358:1118–28.
28. Sato T, Arai E, Kohno T, et al. DNA Methylation Profiles at Precancerous Stages Associated with Recurrence of Lung Adenocarcinoma. PLoS One. 2013;8:e59444.
29. Sandoval J, Mendez-Gonzalez J, Nadal E, et al. A Prognostic DNA Methylation Signature for Stage I Non-small-cell Lung Cancer. J Clin Oncol. 2013;31:4140–7.
30. Robles AI, Arai E, Mathe EA, et al. An Integrated Prognostic Classifier for Stage I Lung Adenocarcinoma Based on mRNA, microRNA, and DNA Methylation Biomarkers. J Thorac Oncol. 2015;10:1037–48.
31. Juergens RA, Wrangel J, Vendetti FP, et al. Combination Epigenetic Therapy has Efficacy in Patients with Refractory Advanced Non-small Cell Lung Cancer. Cancer Discov. 2011;1(7):598–607.
32. Gama-Sosa MA, Slagel VA, Trewyn RW, et al. The 5-methylcytosine Content of DNA from Human Tumors. Nucleic Acids Res. 1983;11:6883–94.
33. Pfeifer GP, Rauch TA. DNA Methylation Patterns in Lung Carcinomas. J Thorac Oncol. 2013;8:e59444.
34. Rauch TA, Zhong X, Wu X, et al. High-resolution Mapping of DNA Hypermethylation and Hypomethylation in Lung Cancer. Proc Natl Acad Sci U S A. 2008;105:252–7.
35. El Messaoudi S, Rollet F, Moullere F, et al. Circulating Cell Free DNA: Preanalytical Considerations. Clin Chim Acta. 2013;424:222–30.
88. Ramirez JL, Rosell R, Taron M, et al. 14-3-3sigma Methylation in Pretreatment Serum Circulating DNA of Cisplatin-plus-gemcitabine-treated Advanced Non-small-cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. J Clin Oncol. 2005;23:9105–12.

89. Wang H, Zhang B, Chen D, et al. Real-time Monitoring Efficiency and Toxicity of Chemotherapy in Patients with Advanced Lung Cancer. Clin Epigenetics. 2015;7:119.

90. Salazar F, Molina MA, Sanchez-Ronco M, et al. Firstline Therapy and Methylation Status of CHFR in Serum Influence Outcome to Chemotherapy Versus EGFR Tyrosine Kinase Inhibitors as Second-line Therapy in Stage IV Non-small-cell Lung Cancer Patients. Lung Cancer. 2011;72:84–91.

91. Desrosiers R, Fridrici K, Rottman F. Identification of Methylated Nucleosides in Messenger RNA from Novikoff Hepatoma Cells. Proc Natl Acad Sci U S A. 1974;71:3971–5.

92. Rottman F, Shatkin AJ, Perry RP. Sequences Containing Methylated Nucleotides at the 5′ Termini of Messenger RNAs: Possible Implications for Processing. Cell. 1974;3:197–9.

93. Kellner S, Burhenne J, Helm M. Detection of RNA Modifications. RNA Biol. 2010;7:217–47.

94. Behm-Ansmant I, Helm M, Motorin Y. Use of Specific Chemical Reagents for Detection of Modified Nucleotides in mRNA. J Nucleic Acids. 2011;2011:408053.

95. Kariikou K, Buckstein M, Ni H, et al. Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA. Immunity. 2005;23:165–75.

96. So EY, Ouchi T. The Application of Toll Like Receptors for Cancer Therapy. Int J Biol Sci. 2010;6:675–81.

97. Zhou Q, Zhu K, Cheng H. Toll-like Receptors in Human Papillomavirus Infection. Arch Immunol Ther Exp (Warsz). 2013;61:203–15.

98. Schichlajakow DV, Logunov DF, Tolkhvatullin AI, et al. Toll-like Receptors (TLRs): the Role in Tumor Progression. Acta Nat. 2010;2:21–9.

99. Ma Y, Han W, et al. Proteinase-activated Receptor 2 Promotes Cancer Cell Migration Through RNA Methylation-mediated Repression of miR-125b. J Biol Chem. 2015;290:6627–37.

100. Zhang C, Zhi WI, Lu H, et al. Hypoxia-Inducible Factors Regulate Pluripotency Factor Expression by ZNF217- and ALKBH5-mediated Modulation of RNA Methylation in Breast Cancer Cells. Oncotarget. 2016;7:64527–42.

101. Matsumoto T, Sato K, Toyokawa S, et al. The Degree of MicroRNA-34b/c Methylation in Serum-circulating DNA is Associated with Malignant Pleural Mesothelioma. Lung Cancer. 2013;82:485–90.

102. Huang W, Qi CB, Lv SW, et al. Determination of DNA and RNA Methylation in Circulating Tumor Cells by Mass Spectrometry. Anal Chem. 2016;88:1378–84.

103. Poynot D, Krecczy PK, Kucharz B, et al. Septin 9 Promoter Region Methylation in Free Circulating DNApotential Role in Noninvasive Diagnosis of Lung Cancer: Preliminary Report. Med Oncol. 2014;31:917.

104. Levine ME, Hosgood HD, Chen B, et al. DNA Methylation Age of Blood Predicts Future Onset of Lung Cancer in the Women’s Health Initiative. Aging (Albany NY). 2015;7:690–700.

105. Hsu HS, Chen TP, Hung C, et al. Characterization of a Multiple Epigenetic Marker Panel for Lung Cancer Detection and Risk Assessment in Plasma. Cancer. 2007;110:2019–26.

106. Matthias W, Klemens V, Ulrike K, et al. Diagnostic Performance of Plasma DNA Methylation Profiles in Lung Cancer, Pulmonary Fibrosis and COPD. EBioMedicine. 2015;2:929–36.

107. Zhang Y, Breiling LP, Balazova Y, et al. Comparison and Combination of Blood DNA Methylation at Smoking-associated Genes and at Lung Cancer-related Genes in Prediction of Lung Cancer Mortality. Int J Cancer. 2016;139:2482–92.